Chinese Journal of Tissue Engineering Research ›› 2025, Vol. 29 ›› Issue (13): 2764-2773.doi: 10.12307/2025.017

Previous Articles     Next Articles

Mechanism of different sources of mesenchymal stem cells in treatment of premature ovarian failure

Liu Yanyan, Ma Yuanyuan, Huang Xianghua, Zhang Jingkun   

  1. The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
  • Received:2023-11-06 Accepted:2024-02-05 Online:2025-05-08 Published:2024-09-11
  • Contact: Zhang Jingkun, MD, Associate professor, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
  • About author:Liu Yanyan, Master candidate, Physician, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
  • Supported by:
    Hebei Provincial Natural Science Foundation, No. H2021206463 (to ZJK); Hebei Province Medical Science Research Project, Nos. 20210080, 20240487 (to ZJK) 

Abstract: BACKGROUND: A large number of cell and animal tests have confirmed the effect of mesenchymal stem cells on improving ovarian function, and some clinical trials have been completed and their effectiveness has been preliminarily confirmed, bringing hope to women with premature ovarian failure.
OBJECTIVE: To summarize and analyze the mechanism, research progress, and related clinical trials of mesenchymal stem cells from different sources in the treatment of premature ovarian failure in recent years, so as to provide a theoretical basis for further research and clinical application of mesenchymal stem cell therapy for premature ovarian failure.
METHODS: Using “mesenchymal stem cells, premature ovarian failure” as keywords in Chinese and English, the relevant literature was searched in CNKI, WanFang Data, Chinese Medical Database, and PubMed database, and finally 72 articles that met the requirements were included for review.
RESULTS AND CONCLUSION: Currently, there are seven types of commonly used mesenchymal stem cells for premature ovarian failure, which are umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, placental mesenchymal stem cells, menstrual blood mesenchymal stem cells, amniotic mesenchymal stem cells, amniotic fluid mesenchymal stem cells, and adipose mesenchymal stem cells. The mechanisms include inhibiting apoptosis and promoting proliferation, anti-inflammatory and inhibiting oxidative stress, homing, promoting angiogenesis, anti-fibrosis, parasecretory, immune regulation, autophagy, and improving microenvironment. Cell and animal experiments have proven that different sources of mesenchymal stem cells can have better intervention effect on premature ovarian failure through various mechanisms, and delay the progress of premature ovarian failure to a certain extent. If it can be successfully applied to the clinic in the future, it can alleviate the psychological and physical pain of patients to a great extent. However, due to the lack of comprehensive and accurate evidence in clinical studies such as stem cell source, administration mode and dose, adverse reactions, etc., further studies are still needed to confirm it in the future, and its long-term safety needs to be further observed.

Key words: ">premature ovarian failure, mesenchymal stem cell, granule cell, ovarian follicle, mechanism, mode of action, clinical trial, diagnosis and treatment

CLC Number: